Fat Malabsorption Alone Does Not Explain GLP-1 and PYY Increases After Gastric Bypass
Blocking fat absorption with orlistat in 5 healthy people did not increase GLP-1, PYY, or satiety, suggesting that post-gastric-bypass hormone changes are not driven by fat malabsorption alone.
Quick Facts
What This Study Found
Short-term orlistat-induced fat malabsorption did not increase postprandial GLP-1 or PYY3-36 levels or affect hunger/satiety in normal-weight individuals.
Key Numbers
5 participants; orlistat 120 mg x 3 days; no change in GLP-1, PYY3-36, hunger, satiety; increased peak glucose and insulin
How They Did This
Randomized, double-blinded, crossover trial with 5 healthy participants receiving orlistat 120mg or placebo for 3 days, with 14-hour meal test measuring hormones and appetite.
Why This Research Matters
Understanding which mechanisms drive beneficial hormone changes after bariatric surgery could help develop non-surgical treatments for obesity using similar pathways.
The Bigger Picture
This negative finding helps narrow the search for what drives post-bypass GLP-1 elevation — ruling out fat malabsorption and pointing toward altered gut anatomy and nutrient delivery patterns.
What This Study Doesn't Tell Us
Very small sample (n=5); short-term (3 days); normal-weight participants — obese individuals may respond differently; orlistat does not perfectly replicate bypass-type malabsorption.
Questions This Raises
- ?What specific mechanism of gastric bypass actually drives the GLP-1 and PYY increases?
- ?Would longer-term fat malabsorption produce different results?
- ?Do obese individuals show different hormonal responses to orlistat than normal-weight people?
Trust & Context
- Key Stat:
- No GLP-1 or PYY increase Orlistat-induced fat malabsorption had no effect on satiety hormones or appetite in 5 healthy participants
- Evidence Grade:
- Well-designed crossover RCT but extremely small sample size (n=5) limits statistical power and generalizability; negative result requires larger confirmation.
- Study Age:
- Published in 2020; the mechanisms driving post-bariatric metabolic improvements continue to be actively investigated.
- Original Title:
- Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety.
- Published In:
- Diabetes, obesity & metabolism, 22(12), 2499-2503 (2020)
- Database ID:
- RPEP-05032
Evidence Hierarchy
Frequently Asked Questions
Why does gastric bypass help with weight loss?
Gastric bypass increases GLP-1 and PYY hormones that reduce appetite. This study found that fat malabsorption alone doesn't explain this, pointing to other mechanisms like altered gut anatomy.
Can orlistat increase GLP-1 like gastric bypass?
No — this study found that blocking fat absorption with orlistat did not increase GLP-1 or PYY levels or reduce appetite in healthy people.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05032APA
Nguyen, Nga N; Kolobova, Irina; Wolfe, Bruce M; Purnell, Jonathan Q. (2020). Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety.. Diabetes, obesity & metabolism, 22(12), 2499-2503. https://doi.org/10.1111/dom.14182
MLA
Nguyen, Nga N, et al. "Short-term intestinal lipase inhibition in normal-weight individuals does not affect postprandial peptide YY3-36 and glucagon-like peptide-1 levels, hunger or satiety.." Diabetes, 2020. https://doi.org/10.1111/dom.14182
RethinkPeptides
RethinkPeptides Research Database. "Short-term intestinal lipase inhibition in normal-weight ind..." RPEP-05032. Retrieved from https://rethinkpeptides.com/research/nguyen-2020-shortterm-intestinal-lipase-inhibition
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.